H. Lundbeck A/S (VIE:LUNB)
Austria · Delayed Price · Currency is EUR | Market Cap | 5.35B +21.3% |
| Revenue (ttm) | 3.41B +11.2% |
| Net Income | 499.07M +14.5% |
| EPS | 0.50 +14.4% |
| Shares Out | n/a |
| PE Ratio | 10.72 |
| Forward PE | 6.49 |
| Dividend | 0.15 (2.78%) |
| Ex-Dividend Date | Mar 19, 2026 |
| Volume | 3 |
| Open | 5.59 |
| Previous Close | 5.55 |
| Day's Range | 5.56 - 5.62 |
| 52-Week Range | 4.57 - 6.40 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 19, 2026 |
About H. Lundbeck
H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomati... [Read more]
Financial Performance
In 2025, H. Lundbeck's revenue was 24.63 billion, an increase of 11.93% compared to the previous year's 22.00 billion. Earnings were 3.19 billion, an increase of 1.56%.
Financial numbers in DKK Financial StatementsNews
Tarek Samad appointed EVP, Head of Research & Development at Lundbeck
VALBY, Denmark, June 24, 2026 /PRNewswire/ -- H. Lundbeck A/S (Lundbeck) today announced that Tarek Samad has been appointed Executive Vice President and Head of Research & Development (R&D) and will ...
Lundbeck drug candidate shows promise in Cushing's disease trial
Danish drugmaker H. Lundbeck said on Sunday its investigational drug asedebart showed encouraging tolerability and results in a small mid-stage study for the treatment of Cushing's disease, a rare ho...
H. Lundbeck Transcript: Study update
Bocunebart, a first-in-class anti-PACAP biologic, showed significant efficacy and a clean safety profile in the phase II-B PROCEED trial for chronic migraine patients with prior treatment failures. The drug achieved a 2.3-day greater reduction in monthly migraine days versus placebo and is positioned to address unmet needs in severe migraine, with phase III planning underway.
H. Lundbeck Press release: Study update
H. Lundbeck issued a press release on June 5, 2026, disclosing material business information to investors.
H. Lundbeck Slides: Study update
H. Lundbeck has posted slides in relation to its latest quarterly earnings report, which was published on June 5, 2026.
Lundbeck's experimental drug cuts migraine days in mid-stage trial
Denmark's Lundbeck said on Thursday its experimental drug bocunebart cut monthly migraine days in a mid-stage study, supporting further development of a new type of treatment for migraine, one of th...
H. Lundbeck Quarterly report: Q1 2026
H. Lundbeck has published its Q1 2026 quarterly earnings report on May 13, 2026.
H. Lundbeck Slides: Q1 2026
H. Lundbeck has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 13, 2026.
H. Lundbeck Earnings Call Transcript: Q1 2026
Q1 2026 saw strong revenue and profit growth, driven by VYEPTI and REXULTI, successful partner market transitions, and pipeline progress. Upgraded guidance reflects robust fundamentals, with continued investment in innovation and disciplined capital allocation.
H. Lundbeck Quarterly report: Q1 2026
H. Lundbeck has published its Q1 2026 quarterly earnings report on May 13, 2026.
H. Lundbeck Slides: Q1 2026
H. Lundbeck has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 13, 2026.
H. Lundbeck Transcript: AGM 2026
Record revenues and profitability were achieved in 2025, with strong growth in strategic brands and a robust pipeline. The board and executive team were re-elected, a new member with neuroscience expertise joined, and all proposals—including a 21% dividend increase—were approved.
H. Lundbeck Slides: FY 2026
H. Lundbeck has posted slides in relation to its FY 2026 quarterly earnings report, which was published on March 18, 2026.
H. Lundbeck Annual report: Q4 2025
H. Lundbeck has published its Q4 2025 annual report on February 4, 2026.
H. Lundbeck Quarterly report: Q4 2025
H. Lundbeck has published its Q4 2025 quarterly earnings report on February 4, 2026.
H. Lundbeck Slides: Q4 2025
H. Lundbeck has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 4, 2026.
H. Lundbeck Transcript: Jefferies Global Healthcare Conference
A focused neuroscience strategy, capital reallocation, and a simplified commercial model have driven strong growth, with VYEPTI and REXULTI as key assets. A diversified, innovation-driven pipeline and dynamic investment approach support upgraded financial guidance and long-term ambitions.
H. Lundbeck Slides: Jefferies Global Healthcare Conference
H. Lundbeck has posted slides in relation to its latest quarterly earnings report, which was published on November 18, 2025.
H. Lundbeck Launches Bid for Avadel in Move to Scuttle Alkermes Deal
The unsolicited bid—worth up to $2.25 billion —potentially upends Avadel's deal to be acquired by Alkermes.
H. Lundbeck Earnings Call Transcript: Q3 2025
Double-digit revenue and profit growth in the first nine months of 2025 were driven by Vyepti and Rexulti, leading to upgraded full-year guidance. Strategic pipeline advances and commercial restructuring support long-term growth, despite FX and generic headwinds.
H. Lundbeck Quarterly report: Q3 2025
H. Lundbeck has published its Q3 2025 quarterly earnings report on November 12, 2025.
H. Lundbeck Slides: Q3 2025
H. Lundbeck has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 12, 2025.
H. Lundbeck Earnings Call Transcript: Q2 2025
Strategic brands drove 21% growth and revenue rose 15% year-over-year, prompting upgraded guidance for both revenue and Adjusted EBITDA. Vyepti and Rexulti led performance, while pipeline and capital reallocation support long-term growth.
H. Lundbeck Quarterly report: Q2 2025
H. Lundbeck has published its Q2 2025 quarterly earnings report on August 14, 2025.
H. Lundbeck Slides: Q2 2025
H. Lundbeck has posted slides in relation to its Q2 2025 quarterly earnings report, which was published on August 14, 2025.